AGE-DIFFERENCES IN CISPLATINUM NEPHROTOXICITY

[1] AGGARWAL SK, 1980, CANCER CHEMOTH PHARM, V4, P249

[2] AGGARWAL SK, 1980, CISPLATIN CURRENT ST, P79

[3] BERRY JP, 1982, CANCER TREAT REP, V66, P1529

[4] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3

[5] Bratton AC, 1939, J BIOL CHEM, V128, P537

[6] BRAUNLICH H, 1983, PHARMAZIE, V38, P483

[7] BRAUNLICH H, 1973, ENTWICKLUNGSPHARMAKO, P127

[8] CHOIE DD, 1981, LAB INVEST, V44, P397

[9] CHOPRA S, 1982, KIDNEY INT, V21, P54, DOI 10.1038/ki.1982.8

[10] CLIFTON GG, 1982, J LAB CLIN MED, V100, P659

[1] AGGARWAL SK, 1980, CANCER CHEMOTH PHARM, V4, P249

[2] AGGARWAL SK, 1980, CISPLATIN CURRENT ST, P79

[3] BERRY JP, 1982, CANCER TREAT REP, V66, P1529

[4] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3

[5] Bratton AC, 1939, J BIOL CHEM, V128, P537

[6] BRAUNLICH H, 1983, PHARMAZIE, V38, P483

[7] BRAUNLICH H, 1973, ENTWICKLUNGSPHARMAKO, P127

[8] CHOIE DD, 1981, LAB INVEST, V44, P397

[9] CHOPRA S, 1982, KIDNEY INT, V21, P54, DOI 10.1038/ki.1982.8

[10] CLIFTON GG, 1982, J LAB CLIN MED, V100, P659